drugset / Trial / NCT04637152

Sacubitril/Valsartan in Resistant Hypertension

NCT04637152

RandomizedParallel-groupSingle-blindTreatment

Summary

The present study aims to evaluate the antihypertensive effect of sacubitril/valsartan in patients with resistant hypertension compared to the use of recommended and optimized antihypertensive therapy, through a randomized clinical trial, over 12 weeks.

Timeline

Start
2020-11-11
Primary completion
2022-07-22
Completion
2022-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril-Valsartan Unknown 97 mg Oral
Subject Sacubitril-Valsartan Unknown 103 mg Oral